tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market
Advertisement

Alnylam Pharma (ALNY) Stock Forecast & Price Target

Compare
1,333 Followers
See the Price Targets and Ratings of:

ALNY Analyst Ratings

Strong Buy
27Ratings
Strong Buy
22 Buy
5 Hold
0 Sell
Based on 27 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$464.05
▲(0.78% Upside)
Based on 27 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $464.05 with a high forecast of $583.00 and a low forecast of $290.00. The average price target represents a 0.78% change from the last price of $460.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"234":"$234","409":"$409","584":"$584","321.5":"$321.5","496.5":"$496.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":583,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$583.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":464.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$464.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$290.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[234,321.5,409,496.5,584],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,460.65,470.0615384615384,479.4730769230769,488.88461538461536,498.29615384615386,507.7076923076923,517.1192307692307,526.5307692307692,535.9423076923076,545.3538461538461,554.7653846153846,564.176923076923,573.5884615384615,{"y":583,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,460.65,460.91153846153844,461.1730769230769,461.43461538461537,461.69615384615383,461.9576923076923,462.21923076923076,462.4807692307692,462.7423076923077,463.00384615384615,463.2653846153846,463.5269230769231,463.78846153846155,{"y":464.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,460.65,447.5230769230769,434.3961538461538,421.2692307692308,408.14230769230767,395.0153846153846,381.8884615384615,368.76153846153846,355.63461538461536,342.5076923076923,329.38076923076926,316.25384615384615,303.12692307692305,{"y":290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":276.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":460.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$583.00Average Price Target$464.05Lowest Price Target$290.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ALNY
H.C. Wainwright
H.C. Wainwright
$570
Buy
23.79%
Upside
Reiterated
10/10/25
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
RBC Capital Analyst forecast on ALNY
RBC Capital
RBC Capital
Buy
Reiterated
10/08/25
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Stifel Nicolaus Analyst forecast on ALNY
Stifel Nicolaus
Stifel Nicolaus
$441$495
Buy
7.50%
Upside
Reiterated
10/06/25
Alnylam price target raised to $495 from $441 at StifelAlnylam price target raised to $495 from $441 at Stifel
Morgan Stanley Analyst forecast on ALNY
Morgan Stanley
Morgan Stanley
$405$475
Hold
3.16%
Upside
Reiterated
10/06/25
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley
Bernstein
$471
Buy
2.29%
Upside
Reiterated
09/26/25
We rate ALNY and REGN Outperform.
Bank of America Securities Analyst forecast on ALNY
Bank of America Securities
Bank of America Securities
$453$520
Buy
12.93%
Upside
Reiterated
09/17/25
Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform ExpansionWe revise our ALNY model following the recent $575mn convertible senior note offering and strong initial trends in the ATTR-CM launch reinforcing our confidence in the commercial opportunity. We view the launch of Amvuttra in ATTR-CM as a pivotal point for the company providing a significant source of long-term revenues to support expansion of the siRNA platform into several additional indications. We also highlight next-gen asset, nucresiran, could be a significant long-term value driver in the ATTR franchise given its more convenient every 6-month dosing, longer IP protection and no royalty burden compared to Amvuttra. We remain bullish on the commercial opportunity for ATTR-CM, which we see as the key value driver, and await upcoming updates for the Amvuttra launch. We reiterate our Buy with new $520 PO (prev. $453; model changes inside).
Goldman Sachs Analyst forecast on ALNY
Goldman Sachs
Goldman Sachs
$504$566
Buy
22.92%
Upside
Reiterated
09/16/25
Goldman Sachs Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on ALNY
Evercore ISI
Evercore ISI
$280$515
Buy
11.84%
Upside
Reiterated
09/11/25
Evercore ISI Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TD Cowen Analyst forecast on ALNY
TD Cowen
TD Cowen
$482
Buy
4.68%
Upside
Reiterated
09/02/25
Alnylam Pharma (ALNY) Receives a Buy from TD Cowen
Citi
$527$583
Buy
26.61%
Upside
Reiterated
09/02/25
Citi Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Truist Financial Analyst forecast on ALNY
Truist Financial
Truist Financial
Buy
Reiterated
09/02/25
Truist Financial Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Leerink Partners Analyst forecast on ALNY
Leerink Partners
Leerink Partners
$343$347
Hold
-24.64%
Downside
Reiterated
09/02/25
Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
UBS
$550
Buy
19.45%
Upside
Reiterated
09/02/25
Positive Outlook on Alnylam Pharma's Hypertension and ATTR-CM Developments
Piper Sandler Analyst forecast on ALNY
Piper Sandler
Piper Sandler
$449
Buy
-2.49%
Downside
Reiterated
09/02/25
Alnylam Pharma (ALNY) Gets a Buy from Piper Sandler
William Blair Analyst forecast on ALNY
William Blair
William Blair
Buy
Reiterated
09/01/25
Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic PartnershipsWe discuss the KARDIA-3 data further in the full note, but we expect investor questions to arise from the clinical meaningfulness of the blood pressure improvements at both 3 and 6 months, given that regulators and KOLs see a 5 mmHg benefit as the minimally important difference. We also expect investors to raise questions about thefact the KARDIA-3 study missed the primary endpoint; however, we acknowledge the unique statistical analysis plan here, which negatively impacted the 300 mg dose on the primary endpoint (p=0.04). More importantly to us, 40% of patients dosed in KARDIA-3 did not actually have systolic blood pressure >140 mmHg at baseline reading (25% had <135 mmHg) and this may have diluted the treatment effect since a substantial number of participants were not stage 2 hypertensive.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ALNY
H.C. Wainwright
H.C. Wainwright
$570
Buy
23.79%
Upside
Reiterated
10/10/25
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
RBC Capital Analyst forecast on ALNY
RBC Capital
RBC Capital
Buy
Reiterated
10/08/25
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Stifel Nicolaus Analyst forecast on ALNY
Stifel Nicolaus
Stifel Nicolaus
$441$495
Buy
7.50%
Upside
Reiterated
10/06/25
Alnylam price target raised to $495 from $441 at StifelAlnylam price target raised to $495 from $441 at Stifel
Morgan Stanley Analyst forecast on ALNY
Morgan Stanley
Morgan Stanley
$405$475
Hold
3.16%
Upside
Reiterated
10/06/25
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley
Bernstein
$471
Buy
2.29%
Upside
Reiterated
09/26/25
We rate ALNY and REGN Outperform.
Bank of America Securities Analyst forecast on ALNY
Bank of America Securities
Bank of America Securities
$453$520
Buy
12.93%
Upside
Reiterated
09/17/25
Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform ExpansionWe revise our ALNY model following the recent $575mn convertible senior note offering and strong initial trends in the ATTR-CM launch reinforcing our confidence in the commercial opportunity. We view the launch of Amvuttra in ATTR-CM as a pivotal point for the company providing a significant source of long-term revenues to support expansion of the siRNA platform into several additional indications. We also highlight next-gen asset, nucresiran, could be a significant long-term value driver in the ATTR franchise given its more convenient every 6-month dosing, longer IP protection and no royalty burden compared to Amvuttra. We remain bullish on the commercial opportunity for ATTR-CM, which we see as the key value driver, and await upcoming updates for the Amvuttra launch. We reiterate our Buy with new $520 PO (prev. $453; model changes inside).
Goldman Sachs Analyst forecast on ALNY
Goldman Sachs
Goldman Sachs
$504$566
Buy
22.92%
Upside
Reiterated
09/16/25
Goldman Sachs Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on ALNY
Evercore ISI
Evercore ISI
$280$515
Buy
11.84%
Upside
Reiterated
09/11/25
Evercore ISI Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TD Cowen Analyst forecast on ALNY
TD Cowen
TD Cowen
$482
Buy
4.68%
Upside
Reiterated
09/02/25
Alnylam Pharma (ALNY) Receives a Buy from TD Cowen
Citi
$527$583
Buy
26.61%
Upside
Reiterated
09/02/25
Citi Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Truist Financial Analyst forecast on ALNY
Truist Financial
Truist Financial
Buy
Reiterated
09/02/25
Truist Financial Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Leerink Partners Analyst forecast on ALNY
Leerink Partners
Leerink Partners
$343$347
Hold
-24.64%
Downside
Reiterated
09/02/25
Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
UBS
$550
Buy
19.45%
Upside
Reiterated
09/02/25
Positive Outlook on Alnylam Pharma's Hypertension and ATTR-CM Developments
Piper Sandler Analyst forecast on ALNY
Piper Sandler
Piper Sandler
$449
Buy
-2.49%
Downside
Reiterated
09/02/25
Alnylam Pharma (ALNY) Gets a Buy from Piper Sandler
William Blair Analyst forecast on ALNY
William Blair
William Blair
Buy
Reiterated
09/01/25
Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic PartnershipsWe discuss the KARDIA-3 data further in the full note, but we expect investor questions to arise from the clinical meaningfulness of the blood pressure improvements at both 3 and 6 months, given that regulators and KOLs see a 5 mmHg benefit as the minimally important difference. We also expect investors to raise questions about thefact the KARDIA-3 study missed the primary endpoint; however, we acknowledge the unique statistical analysis plan here, which negatively impacted the 300 mg dose on the primary endpoint (p=0.04). More importantly to us, 40% of patients dosed in KARDIA-3 did not actually have systolic blood pressure >140 mmHg at baseline reading (25% had <135 mmHg) and this may have diluted the treatment effect since a substantial number of participants were not stage 2 hypertensive.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

1 Month
xxx
Success Rate
20/35 ratings generated profit
57%
Average Return
+1.15%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +1.15% per trade.
3 Months
xxx
Success Rate
22/31 ratings generated profit
71%
Average Return
+11.62%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.97% of your transactions generating a profit, with an average return of +11.62% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
28/31 ratings generated profit
90%
Average Return
+43.36%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 90.32% of your transactions generating a profit, with an average return of +43.36% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
100%
Average Return
+93.49%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +93.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
5
3
1
0
0
Buy
35
41
41
48
35
Hold
15
13
15
15
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
57
57
63
45
In the current month, ALNY has received 35 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 464.05.
Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is $0.46 with a range of -$1.10 to $2.67. The previous quarter’s EPS was -$0.51. ALNY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ALNY has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ALNY is $0.46 with a range of -$1.10 to $2.67. The previous quarter’s EPS was -$0.51. ALNY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ALNY has Preformed in-line its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $932.04M with a range of $654.00M to $1.26B. The previous quarter’s sales results were $773.69M. ALNY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ALNY has Preformed in-line its overall industry.
Next quarter’s sales forecast for ALNY is $932.04M with a range of $654.00M to $1.26B. The previous quarter’s sales results were $773.69M. ALNY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ALNY has Preformed in-line its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 464.05.
    What is ALNY’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 0.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALNY a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 22 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s price target?
            The average price target for Alnylam Pharmaceuticals is 464.05. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $583.00 ,the lowest forecast is $290.00. The average price target represents 0.78% Increase from the current price of $460.46.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 27 Wall Streets Analysts.
                How can I buy shares of ALNY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis